Claudio HoldCo A/S - CVR: 38205072

2022, DKK

05.07.2023

Bruttoresultat

Na.

Primær drift

-1.744'

Årets resultat

-193''

Aktiver

2.749''

Kortfristede aktiver

1.245''

Egenkapital

900''

Afkastningsgrad

-0 %

Soliditetsgrad

33 %

Likviditetsgrad

67 %

Resultat

05.07.2023

Årsrapport	2022 05.07.2023	2021 28.06.2022	2020 16.04.2021	2019 20.04.2020	2018 20.05.2019	2016 26.03.2018
Nettoomsætning		0	0	0	859.000.000	0
Resultat af primær drift	-1.744.000	-437.000	-352.000	4.000	-108.000	-920.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0
Finansielle indtægter	42.000	2.522.000	1.386.000	0	0	0
Finansieringsomkostninger	-4.989.000	-32.488.000	-38.236.000	-43.047.000	-48.357.000	-42.173.000
Andre finansielle omkostninger	0	0	0	0	0	0
Resultat før skat	-193.300.000	-91.219.000	16.873.000	-62.047.000	-106.358.000	-39.968.000
Resultat	-193.300.000	-93.205.000	17.151.000	-57.571.000	-101.165.000	-34.672.000
Forslag til udbytte	0	0	0	0	0	0

Aktiver

05.07.2023

Årsrapport	2022 05.07.2023	2021 28.06.2022	2020 16.04.2021	2019 20.04.2020	2018 20.05.2019	2016 26.03.2018
Kortfristede varebeholdninger	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.214.357.000	930.050.000	68.593.000	26.509.000	6.748.000	6.087.000
Likvider	30.571.000	432.000	56.000	0	606.000	0
Kortfristede aktiver	1.244.928.000	930.482.000	68.649.000	26.509.000	7.354.000	6.087.000
Immaterielle aktiver og goodwill	0	0	0	0	0	0
Finansielle anlægsaktiver	1.504.459.000	1.671.098.000	1.848.278.000	1.958.275.000	2.175.841.000	2.154.304.000
Materielle aktiver	0	0	0	0	0	0
Langfristede aktiver	1.504.459.000	1.671.098.000	1.848.278.000	1.958.275.000	2.175.841.000	2.154.304.000
Aktiver	2.749.387.000	2.601.580.000	1.916.927.000	1.984.784.000	2.183.195.000	2.160.391.000

Aktiver

05.07.2023

Passiver

05.07.2023

Årsrapport	2022 05.07.2023	2021 28.06.2022	2020 16.04.2021	2019 20.04.2020	2018 20.05.2019	2016 26.03.2018
Forslag til udbytte	0	0	0	0	0	0
Egenkapital	899.882.000	1.074.331.000	1.163.904.000	1.149.531.000	1.204.404.000	1.220.990.000
Hensatte forpligtelser	0	0	0	0	0	0
Langfristet gæld til banker	0	0	654.845.000	740.962.000	822.104.000	0
Anden langfristet gæld	0	0	215.000	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0
Kortfristede forpligtelser	1.849.505.000	1.527.249.000	97.963.000	94.291.000	156.687.000	81.131.000
Gældsforpligtelser	1.849.505.000	1.527.249.000	753.023.000	835.253.000	978.791.000	939.372.000
Forpligtelser	1.849.505.000	1.527.249.000	753.023.000	835.253.000	978.791.000	939.372.000
Passiver	2.749.387.000	2.601.580.000	1.916.927.000	1.984.784.000	2.183.195.000	2.160.391.000

Passiver

05.07.2023

Nøgletal

05.07.2023

Årsrapport	2022 05.07.2023	2021 28.06.2022	2020 16.04.2021	2019 20.04.2020	2018 20.05.2019	2016 26.03.2018
Afkastningsgrad	-0,1 %	0,0 %	0,0 %	0,0 %	0,0 %	0,0 %
Dækningsgrad
Resultatgrad	Na.	Na.	Na.	Na.	-11,8 %	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-21,5 %	-8,7 %	1,5 %	-5,0 %	-8,4 %	-2,8 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-35,0 %	-1,3 %	-0,9 %	0,0 %	-0,2 %	-2,2 %
Soliditestgrad	32,7 %	41,3 %	60,7 %	57,9 %	55,2 %	56,5 %
Likviditetsgrad	67,3 %	60,9 %	70,1 %	28,1 %	4,7 %	7,5 %

Resultat

05.07.2023

Gæld

05.07.2023

Årsrapport

05.07.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 05.07.2023)

Information om virksomhedens regnskabsklasse:The annual report of Claudio HoldCo A/S for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

05.07.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-30

Oplysning om usædvanlige forhold:As per 31 December 2022, the companies liquidity ratio is below 100, which could indicate uncertainties around the companies liquidity. The company’s structural financing is anchored in PMI’s overall financial strategy and structure and hence based on intercompany loans from the PMI-group. As a part of this strategy, 1. 267 mDKK of the short-term intercompany debt has been converted to a long-term intercompany loan as per 1 March 2023. In addition the company has been granted a 1. 900 mDKK short-term intercompany facility to support the continues development of the company, incl. support to the overall PMI strategy. It is Managements assessment that the provided funding is sufficient to support the companies strategic business plans for the coming year.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Claudio HoldCo A/S for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business Activities Claudio HoldCo A/S (Claudio HoldCo or ”the Group”) was founded in 2016 with the purpose of investing in the fully owned subsidiaries Fertin Pharma A/S, NordicCan A/S and NCP NextGen A/S. The Group is a specialist Contract Development and Manufacturing Organization (“CDMO”) offering innovative, high-quality pharmaceutical and nutraceutical products for oral and intra-oral delivery. The Group’s current main product formats (“delivery systems”) are chewing gum, lozenges, powders, fast dissolvable tablets, Zapliq® chewables, and Zapliq® chewing gum. The Group is the world’s largest independent developer and manufacturer of medicated chewing gum and has over recent years expanded into other specialized solid dosage oral and intra-oral delivery systems. The Group strives to develop innovative oral and intra-oral delivery systems that offer convenient and pleasurable delivery of active pharmaceutical ingredients (“APIs") and nutraceutical ingredients (“AIs") to patients and consumers. In 2021, the largest category continues to be high-quality chewing gum and lozenges systems applied within Nicotine Replacement Therapy (“NRT”) category. Following the current diversification strategy, the Group is still utilizing its highly flexible delivery systems to grow business outside the NRT category, applying a wider range of APIs and AIs for OTC pharma and nutraceutical categories. During 2021, execution of the strategy has been materially impacted by the COVID-19 pandemic, which has caused delays in customer’s plans to bring new products to market. The Group is headquartered in Vejle, Denmark, where it owns and operates US FDA and EU GMP approved R&D and manufacturing facilities. Furthermore, the Group owns and operates commercial, R&D and manufacturing facilities in India and Canada. In 2022 Claudio Bidco has merged with its sole Parent Company, Claudio HoldCo. The new entity continuous under the Claudio HoldCo name. Business Review and Outlook In 2022, following the COVID-19 pandemic and customer’s related general hesitation in bringing new products to market, Fertin Pharma has realigned its focus in execution of the planned diversification of the business, aimed at growing the product and customer base across delivery platforms, API’s, and nutraceutical ingredients as well as geographies. During 2022, the business has still been challenged by delayed effects from COVID-19, impacting sales of existing products across all categories as well as having resulted in customers postponing and - in some cases - cancelling their planned commercial launches of new products. Positively, we have – during 2022 – seen a material increase in customers interest in revitalising projects aimed at bringing new products to the market. The NRT category still forms the backbone of the business and has also proven to be the least affected by COVID-19 pandemic, compared to products in other categories more recently introduced to the market. Following PMI’s acquisition of the Claudio Holdco, the Group has been highly engaged in supporting PMI’s strategy towards a smoke-free future. These added activities have materially impacted the Group’s cost structure. Apart from the effects described in the previous sections, the 2022 financial result has been materially affected by extraordinary inflation in energy and raw material prices, compared to previous years. Despite the negative effects from COVID-19 and extraordinary inflation, the Company has continued execute the planned investment program in R&D and CAPEX throughout 2022, supporting the diversification strategy and future growth. Moreover, initiatives have been implemented to manage the increased costs. Management expects the 2023 result to continue to be materially impacted by negative development in raw materials, logistics and energy prices. However, because of the implemented initiatives and stronger customer demand, management expects the 2023 result to improve beyond 2022. Revenue is expected in the range of 900 to 1,100 mDKK.